ALBIREO PHARMA,INC. (NASDAQ:ALBO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On March 15, 2018, Albireo Pharma, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2017. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

The following exhibit is furnished with this report:

ALBIREO PHARMA, INC. Exhibit
EX-99.1 2 albo-ex991_14.htm EX-99.1 albo-ex991_14.htm EX 99.1     Albireo Reports Fourth Quarter and Year-End 2017 Financial Results   — Phase 3 PFIC trial of IBAT inhibitor A4250 planned to initiate in spring 2018 — — Elobixibat approved in Japan,…
To view the full exhibit click here